CY1119232T1 - Ενα διφαινυλοσουλφοναμιδιο ανταγωνιστης του υποδοχεα της ενδοθηλινης και της αγγειοτενσινης ii για τη θεραπεια της σπειραματοσκληρυνσης - Google Patents
Ενα διφαινυλοσουλφοναμιδιο ανταγωνιστης του υποδοχεα της ενδοθηλινης και της αγγειοτενσινης ii για τη θεραπεια της σπειραματοσκληρυνσηςInfo
- Publication number
- CY1119232T1 CY1119232T1 CY20171100811T CY171100811T CY1119232T1 CY 1119232 T1 CY1119232 T1 CY 1119232T1 CY 20171100811 T CY20171100811 T CY 20171100811T CY 171100811 T CY171100811 T CY 171100811T CY 1119232 T1 CY1119232 T1 CY 1119232T1
- Authority
- CY
- Cyprus
- Prior art keywords
- component
- treatment
- angiotensin
- spiramatology
- endothiline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Αποκαλύπτονται μέθοδοι χορήγησης και φαρμακευτικές συνθέσεις μιας ένωσης διφαινυλο σουλφοναμιδίου, η οποία είναι ένας διπλός ανταγωνιστής του υποδοχέα της αγγειοτενσίνης και της ενδοθηλίνης, για τη θεραπεία ασθενειών.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16544709P | 2009-03-31 | 2009-03-31 | |
US16541909P | 2009-03-31 | 2009-03-31 | |
EP10759268A EP2413930A4 (en) | 2009-03-31 | 2010-03-29 | ORAL FORMULATIONS OF DIPHENYL SULFONAMIDE DOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS FOR THE TREATMENT OF INCREASED BLOOD PRESSURE AND DIABETIC NEPHROPATHY |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1119232T1 true CY1119232T1 (el) | 2018-02-14 |
Family
ID=42828649
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100811T CY1119232T1 (el) | 2009-03-31 | 2017-07-28 | Ενα διφαινυλοσουλφοναμιδιο ανταγωνιστης του υποδοχεα της ενδοθηλινης και της αγγειοτενσινης ii για τη θεραπεια της σπειραματοσκληρυνσης |
CY20201100424T CY1123017T1 (el) | 2009-03-31 | 2020-05-08 | Ενα διφαινυλοσουλφοναμιδιο ανταγωνιστης του υποδοχεα της ενδοθηλινης και της αγγειοτενσινης ii για τη θεραπεια της σπειραματοσκληρυνσης και της επαγομενης απο iga νεφροπαθειας |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100424T CY1123017T1 (el) | 2009-03-31 | 2020-05-08 | Ενα διφαινυλοσουλφοναμιδιο ανταγωνιστης του υποδοχεα της ενδοθηλινης και της αγγειοτενσινης ii για τη θεραπεια της σπειραματοσκληρυνσης και της επαγομενης απο iga νεφροπαθειας |
Country Status (16)
Country | Link |
---|---|
US (4) | US20140142149A1 (el) |
EP (4) | EP3222277B1 (el) |
JP (3) | JP2012522058A (el) |
CN (2) | CN104107176A (el) |
CY (2) | CY1119232T1 (el) |
DK (2) | DK2732818T3 (el) |
ES (2) | ES2636087T3 (el) |
FI (1) | FIC20240031I1 (el) |
HK (1) | HK1244687A1 (el) |
HR (2) | HRP20171197T1 (el) |
HU (2) | HUE049450T2 (el) |
LT (2) | LT3222277T (el) |
PL (2) | PL3222277T3 (el) |
PT (2) | PT2732818T (el) |
SI (2) | SI3222277T1 (el) |
WO (1) | WO2010114801A1 (el) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2596026B1 (en) | 2010-07-23 | 2020-04-08 | Trustees of Boston University | Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery |
AR083417A1 (es) | 2010-10-14 | 2013-02-21 | Novartis Ag | Composiciones farmaceuticas que contienen un dgat1 inhibidor |
US20130022551A1 (en) * | 2011-07-22 | 2013-01-24 | Trustees Of Boston University | DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS |
RU2661402C2 (ru) * | 2011-10-17 | 2018-07-16 | Лексикон Фармасьютикалз, Инк. | Твердые дозированные формы (s)-этил 2-амино-3-(4-(2-амино-6((r)-1-(4-хлор-2-(3-метил-1н-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропаноата |
WO2013102145A1 (en) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
HUE035069T2 (en) | 2011-12-28 | 2018-05-02 | Global Blood Therapeutics Inc | Substituted benzaldehyde compounds and their use to increase tissue oxygenation |
WO2013149258A2 (en) | 2012-03-30 | 2013-10-03 | Charles Drew University of Medicine and Science | Compositions and methods for treating or preventing metabolic syndrome disorders |
US20140271923A1 (en) | 2013-03-14 | 2014-09-18 | Christopher Brian Reid | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
CA2903022C (en) | 2013-03-15 | 2021-11-09 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
KR20150132146A (ko) | 2013-03-15 | 2015-11-25 | 글로벌 블러드 테라퓨틱스, 인크. | 헤모글로빈 조정을 위한 화합물 및 이의 용도 |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
PE20161035A1 (es) | 2013-03-15 | 2016-11-13 | Global Blood Therapeutics Inc | Compuestos y usos de estos para la modulacion de la hemoglobina |
CN114404414A (zh) | 2013-06-13 | 2022-04-29 | 阿克比治疗有限公司 | 用于治疗贫血症的组合物和方法 |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
KR102448369B1 (ko) | 2014-02-05 | 2022-09-28 | 머크 샤프 앤드 돔 엘엘씨 | Cgrp-활성 화합물에 대한 정제 제제 |
JP6809681B2 (ja) | 2014-02-07 | 2021-01-06 | グローバル ブラッド セラピューティクス インコーポレイテッド | 2−ヒドロキシ−6−((2−(1−イソプロピル−1h−ピラゾール−5−イル)ピリジン−3−イル)メトキシ)ベンズアルデヒドの遊離塩基の結晶多形 |
CN104367576A (zh) * | 2014-10-24 | 2015-02-25 | 南方医科大学南方医院 | 化合物icg-001在制备治疗高血压的药物中的用途 |
CA2995716A1 (en) | 2015-08-24 | 2017-03-02 | Trustees Of Boston University | Anti-despr monoclonal antibody targeted therapy and imaging for cancer and stroke |
TW201731509A (zh) | 2015-12-04 | 2017-09-16 | 全球血液治療公司 | 針對2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之劑量方案 |
TWI663160B (zh) | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
TW202332423A (zh) * | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
CN110049764A (zh) * | 2016-10-13 | 2019-07-23 | 雷特罗芬公司 | 用于治疗肾脏疾病或病症的联苯磺酰胺化合物 |
IL270152B2 (en) * | 2017-04-25 | 2024-10-01 | Proteus Digital Health Inc | Lisinopril preparations with an event marker that can be swallowed |
CN111356475A (zh) | 2017-09-18 | 2020-06-30 | 波士顿大学董事会 | 用于治疗NETosis和中性粒细胞激活的方法 |
WO2019241609A1 (en) | 2018-06-15 | 2019-12-19 | Trustees Of Boston University | Polypeptide compositions and methods for site-specific targeting of therapeutic agents |
EP3860975B1 (en) | 2018-10-01 | 2023-10-18 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
JP7524167B2 (ja) | 2018-10-04 | 2024-07-29 | トラビア セラピューティクス, インコーポレイテッド | Iv型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物 |
AU2019404552A1 (en) * | 2018-12-21 | 2021-07-15 | Travere Therapeutics, Inc. | Amorphous sparsentan compositions |
WO2020136441A1 (en) * | 2018-12-28 | 2020-07-02 | Gnt Pharma Co., Ltd. | Compositions and methods for treating neurodegenerative disorders |
EP3925957A4 (en) | 2019-02-15 | 2022-11-02 | Tohoku University | 1,3-DIOXOLANE DERIVATIVE |
EP4188375A4 (en) | 2020-07-29 | 2024-07-24 | Allergan Pharmaceuticals Int Ltd | TREATMENT OF MIGRAINE |
US11584792B2 (en) | 2020-10-15 | 2023-02-21 | Trustees Of Boston University | Antibody therapies and methods for treating coronavirus infection |
AU2021409718A1 (en) | 2020-12-22 | 2023-07-13 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
WO2022246200A1 (en) | 2021-05-21 | 2022-11-24 | Travere Therapeutics, Inc. | Methods of treating kidney diseases or disorders |
JP7458085B2 (ja) * | 2021-07-28 | 2024-03-29 | 株式会社三協 | 錠剤用崩壊剤及びこれを利用した錠剤 |
AU2022334402A1 (en) | 2021-08-26 | 2024-02-22 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Aromatic ring-containing biological antagonist, and preparation method therefor and use thereof |
CN118284605A (zh) * | 2021-12-28 | 2024-07-02 | 亚克医药株式会社 | 化合物、血管紧张素ii第1型受体拮抗剂及医药组合物 |
WO2024073672A1 (en) | 2022-09-30 | 2024-04-04 | Travere Therapeutics, Inc. | Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders |
CN115636799A (zh) * | 2022-11-04 | 2023-01-24 | 苏州莱安医药化学技术有限公司 | 一种双效内皮素-血管紧张素受体拮抗剂的制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US793898A (en) | 1905-03-01 | 1905-07-04 | William Mcintosh | Locomotive-tender frame. |
US1395298A (en) | 1919-11-20 | 1921-11-01 | Walter H Richman | Container |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
IL140622A0 (en) * | 1998-07-06 | 2002-02-10 | Bristol Myers Squibb Co | Biphenyl sufonamide derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof |
US6638937B2 (en) * | 1998-07-06 | 2003-10-28 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
US6380184B1 (en) | 1998-10-28 | 2002-04-30 | Bristol-Myers Squibb Co. | Benzoazepines and analogs thereof useful as growth hormone secretagogues |
CA2360305A1 (en) | 1999-02-09 | 2000-08-17 | Bristol-Myers Squibb Company | Lactam inhibitors of fxa and method |
US6518292B1 (en) | 1999-03-12 | 2003-02-11 | Bristol-Myers Squibb Co. | Heterocyclic aromatic compounds usefuls as growth hormone secretagogues |
US7390824B1 (en) | 1999-09-07 | 2008-06-24 | Bristol-Myers Squibb Company | Method for treating diabetes employing an aP2 inhibitor and combination |
US6586438B2 (en) | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
ATE339417T1 (de) * | 1999-12-15 | 2006-10-15 | Bristol Myers Squibb Co | Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten |
-
2010
- 2010-03-29 EP EP17157697.8A patent/EP3222277B1/en active Active
- 2010-03-29 CN CN201410045095.9A patent/CN104107176A/zh active Pending
- 2010-03-29 EP EP20152292.7A patent/EP3708163A1/en active Pending
- 2010-03-29 ES ES14155459.2T patent/ES2636087T3/es active Active
- 2010-03-29 HU HUE17157697A patent/HUE049450T2/hu unknown
- 2010-03-29 EP EP14155459.2A patent/EP2732818B1/en active Active
- 2010-03-29 LT LTEP17157697.8T patent/LT3222277T/lt unknown
- 2010-03-29 SI SI201032000T patent/SI3222277T1/sl unknown
- 2010-03-29 WO PCT/US2010/029093 patent/WO2010114801A1/en active Application Filing
- 2010-03-29 DK DK14155459.2T patent/DK2732818T3/en active
- 2010-03-29 ES ES17157697T patent/ES2811342T3/es active Active
- 2010-03-29 CN CN2010800188487A patent/CN102421434A/zh active Pending
- 2010-03-29 PL PL17157697T patent/PL3222277T3/pl unknown
- 2010-03-29 PT PT141554592T patent/PT2732818T/pt unknown
- 2010-03-29 PL PL14155459T patent/PL2732818T3/pl unknown
- 2010-03-29 HU HUE14155459A patent/HUE033494T2/en unknown
- 2010-03-29 PT PT171576978T patent/PT3222277T/pt unknown
- 2010-03-29 EP EP10759268A patent/EP2413930A4/en not_active Withdrawn
- 2010-03-29 LT LTEP14155459.2T patent/LT2732818T/lt unknown
- 2010-03-29 DK DK17157697.8T patent/DK3222277T3/da active
- 2010-03-29 JP JP2012503575A patent/JP2012522058A/ja active Pending
- 2010-03-29 SI SI201031505T patent/SI2732818T1/sl unknown
-
2012
- 2012-12-19 US US13/720,452 patent/US20140142149A1/en not_active Abandoned
-
2014
- 2014-11-12 JP JP2014229994A patent/JP2015052001A/ja active Pending
- 2014-11-20 HK HK18104154.4A patent/HK1244687A1/zh unknown
-
2015
- 2015-02-25 US US14/631,768 patent/US9662312B2/en active Active
-
2016
- 2016-08-16 JP JP2016159420A patent/JP2017008081A/ja active Pending
-
2017
- 2017-07-28 CY CY20171100811T patent/CY1119232T1/el unknown
- 2017-08-03 HR HRP20171197TT patent/HRP20171197T1/hr unknown
- 2017-08-25 US US15/687,407 patent/US9993461B2/en active Active
-
2018
- 2018-03-28 US US15/938,956 patent/US20180344705A1/en not_active Abandoned
-
2020
- 2020-04-24 HR HRP20200665TT patent/HRP20200665T1/hr unknown
- 2020-05-08 CY CY20201100424T patent/CY1123017T1/el unknown
-
2024
- 2024-10-01 FI FIC20240031C patent/FIC20240031I1/fi unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119232T1 (el) | Ενα διφαινυλοσουλφοναμιδιο ανταγωνιστης του υποδοχεα της ενδοθηλινης και της αγγειοτενσινης ii για τη θεραπεια της σπειραματοσκληρυνσης | |
CY1120939T1 (el) | Συνδυασμος ρεγοραφενιμπης και ακετυλοσαλικυλικου οξεος για τη θεραπευτικη αντιμετωπιση του ορθοκολικου καρκινου | |
CY1122786T1 (el) | Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης | |
CY1120318T1 (el) | Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων | |
CY1124729T1 (el) | Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου | |
CY1125100T1 (el) | Υδατικο φαρμακευτικο σκευασμα ταπενταδολης για απο του στοματος χορηγηση | |
CY1120429T1 (el) | Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων | |
CY1118379T1 (el) | Αναστολεις ιου ηπατιτιδας c | |
CL2017003351A1 (es) | Anticuerpo anti receptor de transferrina humana que pasan a través de la barrera hematoencefálica. | |
CY1120417T1 (el) | Μεθοδοι για τη μειωση των επιπεδων των βασεοφιλων | |
CY1122853T1 (el) | Σταθερα σκευασματα λινακλοτιδης | |
CY1116645T1 (el) | Ενωση-αναστολεας σηματοδοτικου μονοπατιου notch | |
CY1119007T1 (el) | Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης | |
CY1121315T1 (el) | Απο του στοματος χορηγουμενες συνθεσεις της δεφερασιροξης | |
EA201170441A1 (ru) | Терапевтические противовирусные пептиды | |
CL2014000504A1 (es) | Compuestos derivados de pirimidinas condensadas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o prevencion de la insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades. | |
CL2014001779A1 (es) | Compuestos derivados de pirimidinas y triazinas fusionadas sustituidas; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento y/o prevencion de insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades. | |
EA201201263A1 (ru) | Фармацевтическая композиция, содержащая этексилат дабигатрана | |
EA201201509A1 (ru) | Фармацевтические составы, содержащие пиоглитазон и линаглиптин | |
CY1124331T1 (el) | Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης | |
CY1121999T1 (el) | Φαρμακοτεχνικες μορφες συνδυασμου δαρουναβιρης | |
CY1122313T1 (el) | Ορβεπιταντη για την αγωγη του χρονιου κνησμου | |
CL2012002716A1 (es) | Uso de un compuesto inhibidores de dgat1 porque es útil en la prevención, demora del progreso o el tratamiento de una enfermedad o condición seleccionada a partir de quilomicronemia, síndrome de quilomicronemia familiar e hiperlipoproteinemia tipo v; un compuesto derivado de heteroarilo sustituido; composición farmacéutica. | |
IT1404931B1 (it) | Composizioni oftalmiche per la somministrazione di principi attivi liposolubili . | |
CY1115556T1 (el) | Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη |